-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, VnPsfdCkJOXX07+jpgTXmqQHpwydhdptkZbqfpYjuikFh+5rsKxvnE1s77P19ozm E5z2s743sUPM7bYxaianvQ== 0000891020-02-000734.txt : 20020516 0000891020-02-000734.hdr.sgml : 20020516 20020516150626 ACCESSION NUMBER: 0000891020-02-000734 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20020510 ITEM INFORMATION: Changes in registrant's certifying accountant ITEM INFORMATION: Financial statements and exhibits FILED AS OF DATE: 20020516 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOJECT MEDICAL TECHNOLOGIES INC CENTRAL INDEX KEY: 0000810084 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 931099680 STATE OF INCORPORATION: OR FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-15360 FILM NUMBER: 02654833 BUSINESS ADDRESS: STREET 1: 7620 S W BRIDGEPORT RD CITY: PORTLAND STATE: OR ZIP: 97224 BUSINESS PHONE: 5036397221 MAIL ADDRESS: STREET 1: 7620 S W BRIDGEPORT ROAD CITY: PORTLAND STATE: OR ZIP: 97224 FORMER COMPANY: FORMER CONFORMED NAME: BIOJECT MEDICAL SYSTEMS LTD DATE OF NAME CHANGE: 19920703 8-K/A 1 v81632a1e8-ka.htm FORM 8-K/A e8-ka
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K/A-1

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 10, 2002

BIOJECT MEDICAL TECHNOLOGIES INC.
(Exact name of registrant as specified in its charter)

Commission file number: 0-15360
   
Oregon
(State or other jurisdiction of incorporation
or organization)		 93-1099680
(I.R.S. Employer
Identification No.)
 
7620 SW Bridgeport Road
Portland, Oregon
(Address of principal executive offices)		 97224
(Zip Code)

Registrant’s telephone number, including area code: 503-639-7221

 

Item 4. Changes in Registrant’s Certifying Accountant
Item 7. Financial Statements and Exhibits
SIGNATURES
EXHIBIT 16

Table of Contents

BIOJECT MEDICAL TECHNOLOGIES INC.
FORM 8-K/A-1
INDEX

             
Item   Description   Page
 
 
Item 4.
  
Changes in Registrant’s Certifying Accountant
    2  
 
Item 7.
  
Financial Statements and Exhibits
    2  
 
 
  
Signatures
    3  

1

Table of Contents

Item 4.   Changes in Registrant’s Certifying Accountant

On May 10, 2002, due to the closure of the Portland, Oregon office of Arthur Andersen LLP, the Audit Committee of our Board of Directors approved the dismissal of our independent public accountants, Arthur Andersen LLP. Arthur Andersen LLP’s reports on our financial statements for each of the last two fiscal years did not contain an adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles. Since March 31, 2000, there have not been any disagreements between us and Arthur Andersen LLP on any matters of accounting principles or practices, financial statement disclosure or auditing scope or procedure, or any reportable events as defined under Item 304(a)(1)(v) of Regulation S-K promulgated by the Securities and Exchange Commission.

A copy of a letter addressed to the Securities and Exchange Commission from Arthur Andersen LLP stating that it agrees with the above statements is attached as Exhibit 16.

Also on May 10, 2002, based on the recommendation of the Audit Committee of our Board of Directors, we engaged the firm of KPMG LLP to be our independent public accountants. We did not consult KPMG LLP at any time since March 31, 2000 with respect to the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on our financial statements, or concerning any disagreement or reportable event with Arthur Andersen LLP.

Item 7.   Financial Statements and Exhibits
     
Exhibits:
16   Letter re change in certifying accountant

2

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
   
Date: May 13, 2002 BIOJECT MEDICAL TECHNOLOGIES INC.
(Registrant)
 
  /s/  JOHN GANDOLFO
Chief Financial Officer
(Principal Financial and Accounting Officer)

3 EX-16 3 v81632a1ex16.txt EXHIBIT 16 EXHIBIT 16 May 10, 2002 Office of the Chief Accountant Securities and Exchange Commission 450 Fifth Street, N.W. Washington, D.C. 20549 Dear Sir/Madam: We have read Item 4 included in the Form 8-K dated May 10, 2002 of Bioject Medical Technologies Inc. to be filed with the Securities and Exchange Commission and are in agreement with the statements contained therein. Very truly yours, Arthur Andersen LLP Cc: John Gandolfo Chief Financial Officer Bioject, Inc -----END PRIVACY-ENHANCED MESSAGE-----